Abstract PS3-08-17: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene signature benefit from (Neo)adjuvant chemotherapy (CT): Real World FLEX Study

Clinical Cancer Research 2026

View at publisher
Authors: R. L. Mahtani, H. Wildiers, S. Lin, S. Ana, Anna Schreiber, Lauren Carcas, N. Dempsey, V. Poillucci, Michelle Landon, Christa Dreezen, Harshini Ramaswamy, William M. Audeh
+1 more Joyce O’Shaughnessy
DOI: 10.1158/1557-3265.sabcs25-ps3-08-17
Cited by: 0

Abstract

Abstract BACKGROUND: Women ≥70 are less likely to receive CT due to quality-of-life concerns and comorbidities. These patients (pts) are underrepresented in studies assessing the utility of genomic profiling to guide CT decisions. To identify the utility of a 70-gene recurrence risk assay MammaPrint (MP) we examined the relationship of age (≥70 vs

Fields of Study & Subjects

Breast Cancer Treatment Studies BRCA gene mutations in cancer Gastric Cancer Management and Outcomes

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PS3–08
Publication date
17 February 2026
Language
EN